Omalizumab (Xolair)

An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.

Also Known As:

Networked: 2445 relevant articles (602 outcomes, 593 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Maurer, Marcus: 62 articles (01/2022 - 09/2010)
2.	Casale, Thomas B: 25 articles (01/2022 - 12/2003)
3.	Metz, Martin: 22 articles (01/2022 - 09/2010)
4.	Canonica, Giorgio Walter: 20 articles (06/2021 - 07/2007)
5.	Ortiz, Benjamin: 20 articles (01/2021 - 01/2017)
6.	Bernstein, Jonathan A: 18 articles (01/2022 - 09/2015)
7.	Busse, William W: 18 articles (01/2021 - 09/2004)
8.	Staubach, Petra: 16 articles (03/2022 - 09/2010)
9.	Thomsen, Simon Francis: 16 articles (01/2022 - 01/2012)
10.	Maurer, M: 16 articles (01/2021 - 02/2011)

Related Diseases

1.	Asthma (Bronchial Asthma) 11/01/2005 - "Responder analysis shows that omalizumab provides the greatest benefit in patients with more severe asthma, and this has been confirmed by recent studies establishing the efficacy of omalizumab in patients whose asthma is poorly controlled despite receiving the best standard care in medication. " 01/01/2023 - "Whereas most economic evaluations are based on aggregate data, this independent cost-effectiveness analysis using prospective real-world patient-level data suggests that omalizumab in combination with standard of care is cost-effective for severe asthma from the Turkish public payer perspective. " 01/01/2019 - "Omalizumab is now widely used to treat severe allergic asthma in children and is highly effective for asthma exacerbations and asthma control with a good safety profile. " 03/01/2015 - "Omalizumab improved most clinical parameters of Mexican patients with difficult-to-control asthma. " 04/01/2011 - "Omalizumab has been shown to be highly effective in treating children and adults with moderate to severe allergic asthma. "
2.	Chronic Urticaria 11/20/2021 - "Omalizumab is the best treatment for patients with chronic spontaneous urticaria (CSU). " 01/01/2021 - "Omalizumab (OMA) is highly effective for refractory chronic spontaneous urticaria (CSU), but its high cost exerts a great economic burden on patients and society. " 07/01/2018 - "Omalizumab is highly effective in controlling chronic spontaneous urticaria (CSU) symptoms; however, patients can experience symptom return on treatment discontinuation. " 04/01/2017 - "Omalizumab 300 mg administered every 4 weeks appears to be the most effective and safe dosage, with a rapid response time, for the treatment of chronic idiopathic urticaria, with few minor adverse effects, and appears to be safe in the offspring of pregnant patients who received the drug. " 02/01/2014 - "Omalizumab is effective in most subsets of chronic urticaria sufferers who do not respond to other treatments but its high cost represents a limitation to its widespread use. "
3.	Urticaria (Hives) 01/01/2020 - "Courses of 5-6 months of omalizumab may induce rapid significant improvement of urticaria and many prolonged complete remissions. " 01/01/2017 - "The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. " 06/01/2016 - "Both patients showed a complete remission of urticaria after the first injection of omalizumab. " 11/01/2012 - "During omalizumab treatment, the urticaria activity score declined significantly (12.11±1.97 to 2.7±4.23; P=0.001) and the CU-quality of life score improved significantly (34.65±13.58 to 60.88±11.11; P=0.004). " 01/01/2011 - "In 1 patient, symptoms improved after increasing the dose of omalizumab, and 1 patient with localized heat urticaria did not respond significantly to treatment. "
4.	Allergic Rhinitis 01/01/2021 - "In this case, omalizumab markedly improved ASD-related and sleep behavior in a 6-year-old with ASD, allergic rhinitis, and autoimmune disorder. " 09/01/2023 - "Omalizumab effectively treated patients with moderate-to-severe allergic rhinitis, and improved their quality of life." 05/05/2016 - "[Safety and efficacy of omalizumab for the treatment of allergic rhinitis:Meta-analysis of randomized clinical trials]." 05/01/2014 - "Studies on the efficacy of omalizumab in allergic rhinitis that assessed clinical outcomes were selected. " 12/01/2016 - "Our data confirm the efficacy of omalizumab in the treatment of allergic rhinitis. "
5.	Atopic Dermatitis (Atopic Eczema) 01/01/2019 - "This report describes an interesting case of severe adult onset difficult-to-treat atopic dermatitis dramatically improved in response to treatment with Omalizumab. " 06/01/2010 - "We present 3 patients with severe, treatment resistant atopic dermatitis whose cutaneous symptoms significantly improved by treatment with omalizumab." 12/01/2016 - "Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis." 09/01/2008 - "Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study." 08/01/2019 - "Smaller studies have evaluated the effects of omalizumab in atopic dermatitis (AD). "

Related Drugs and Biologics

1.	Immunoglobulin E (IgE)
2.	anti-IgE antibodies
3.	Adrenal Cortex Hormones (Corticosteroids)
4.	Histamine Antagonists (Antihistamines)
5.	Monoclonal Antibodies
6.	mepolizumab
7.	Steroids
8.	dupilumab
9.	benralizumab
10.	Allergens

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Aftercare (After-Treatment)
4.	Drug Tapering
5.	Duration of Therapy